GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Earnings per Share (Diluted)

BCAL Diagnostics (ASX:BDX) Earnings per Share (Diluted) : A$-0.02 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Earnings per Share (Diluted)?

BCAL Diagnostics's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was A$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

BCAL Diagnostics's EPS (Basic) for the six months ended in Dec. 2023 was A$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

BCAL Diagnostics's EPS without NRI for the six months ended in Dec. 2023 was A$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.


BCAL Diagnostics Earnings per Share (Diluted) Historical Data

The historical data trend for BCAL Diagnostics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Earnings per Share (Diluted) Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Earnings per Share (Diluted)
-0.02 -0.02

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of BCAL Diagnostics's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, BCAL Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's PE Ratio distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's PE Ratio falls into.



BCAL Diagnostics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

BCAL Diagnostics's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.062-0)/210.903
=-0.02

BCAL Diagnostics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-2.407-0)/231.397
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


BCAL Diagnostics  (ASX:BDX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BCAL Diagnostics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

BCAL Diagnostics (ASX:BDX) Headlines